Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Piper Sandler analyst Adam Maeder maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA ...

They were followed-up at 1, 3 and 6 months and answered surveys about sleep, CPAP side effects and lifestyle. We compared CPAP compliance, cost-effectiveness and QoL between the beginning and the end ...

IIT Bombay has developed an affordable device and app to diagnose and manage tinnitus, a challenging condition affecting millions. This innovation offers precise diagnosis, customizable treatment, and ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea.

(Getty Images) (NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step ...

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s ...